Find a Physician | How to Contribute | About Us | Clinical Trials
Search: 
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Head and neck: Buccal cavity/pharynx

A Phase 1 Open-label, Multicenter Study To Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884), and to Estimate the Maximum Tolerated Dose in Subjects With Advanced or Refractory Cancer

The purpose of this study is to Evaluate the safety, tolerability, and DLTs of AGEN1884 in advanced or metastatic cancer (solid tumors or lymphoma) including but not limited to carcinoma, sarcoma, malignant glioma, or melanoma

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

Multicenter Phase II Study of Nivolumab in Previously Treated Patients with Recurrent and Metastatic Nasopharyngeal Carcinoma

To determine any good and bad effects of the study drug called Nivolumab in previously treated patients with recurrent and metastatic Nasopharyngeal Carcinoma.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects with INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma

This purpose of this study is to determine the safety and effectiveness of a drug called tazemetostat to treat cancer

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054329 in Subjects With Advanced Malignancies

The purpose of this study is to find out how safe and tolerable the study drug INCB054329 is in patients with advanced types of cancer (including solid tumors and blood cancers). This study will mainly answer the following: 1) the maximum dose that can be given to the patient with minimal side effects; 2) the amount of the study drug that enters and leaves the body over time and the effects it has on the body; 3) preliminary evidence of whether or not the drug has any anti-cancer effects.

Status: Accepting New Patients
Principal Investigator: Jason Kaplan

Phase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

The purpose of this research study is to study the effects, good and/or bad of performing surgery through the mouth (what is referred to as transoral surgery) followed by treatment that is selected based on studying the patient's cancer under a microscope by a doctor (called a pathologist), on patients and their human papillomavirus associated oropharynx cancer.

Status: Accepting New Patients
Principal Investigator: Bharat Mittal

TPF Induction chemotherapy and ABT-888 (Veliparib) – a Phase 1/Randomized Phase 2 Study in Patients w/ Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck

The purpose of this study is to see how safe and effective ABT-888 is, when combined with chemotherapy, at shrinking cancer.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

The study will be done in two parts. In Part 1 of the study, patients with lung, colorectal, or head and neck cancer will receive study drug MM-151 in combination with study drug MM-121. The purpose is to determine a safe dose of MM-151 plus MM-121 combination that does not cause unacceptable side effects. This is also referred to as maximum tolerated dose (MTD). MTD will be determined by evaluating the safety and tolerability of MM-151 when combined with MM-121 at different doses. In Part 2 of the study, only patients who have colorectal cancer will receive study drug MM-151 combined with study drug MM-121. The purpose is to continue to evaluate safety and tolerability of dose found in Part 1 as well as to evaluate response of patient’s body and cancer to this combination of study drugs.

Status: Accepting New Patients
Principal Investigator: Benedito Carneiro

A Phase 1 Study to Evaluate the Safety, Tolerability, and Efficacy of MEDI4736 in Combination with Tremelimumab or Tremelimumab Alone in Subjects with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

This study will occur in two parts, Dose-exploration (Part 1) and Dose-expansion (Part 2). The main purpose of Part 1 is to determine the doses and dosing schedule of both MEDI4736 and tremelimumab that are safe and tolerable when given together in subjects with certain types of head and neck cancer. The main purpose of Part 2 is to continue to assess the safety and tolerability of the MEDI4736 and tremelimumab doses and dosing schedule determined by the Sponsor during Part 1 and to assess the safety and tolerability of tremelimumab when administered alone.

Status: Accepting New Patients
Principal Investigator: Mark Agulnik

An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti-FGFR2 Antibody Drug Conjugate Bay 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2

The purpose of this study is to evaluate the safety, tolerability (the effect of the study drug on the body), of BAY 1187982 when given as a single agent in patients with advance or refractory (has not responded to other treatment) solid tumors.

Status: Accepting New Patients
Principal Investigator: Aparna Kalyan

Randomized Phase II And Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

The main purpose of this study is to see if a longer progression free survival time for nasopharyngeal cancer can be obtained by individualizing treatment based on certain biomarkers.

Status: Accepting New Patients
Principal Investigator: Bharat Mittal

REDEFINE AYAO: Reducing Emotional Distress, Enhancing Function and Improving Network Engagement in Adolescent and Young Adult Oncology

The purpose of this study is to test an 8-week stress reduction course that is intended to reduce anxiety and improve the quality of life of adolescents and young adults diagnosed with cancer. This study will include a total of 100 participants, all of whom have been diagnosed with cancer.

Status: Accepting New Patients
Principal Investigator: David Victorson

A Randomized Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Repetitive Transcranial Magnetic Stimulation in Cancer Patients with Depression and Anxiety

The purpose of this study is to test the safety and tolerability of left- and right-sided rTMS as a treatment for depression in the cancer population.

Status: Accepting New Patients
Principal Investigator: Mehmet Dokucu

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI6383 Alone and in Combination with MEDI4736 in Adult Subjects with Select Advanced Solid Tumors (Amendment 2 title)

The main purpose of this study is to determine the best dose of MEDI6383 that is safe and tolerable in subjects with advanced solid tumors.

Status: Accepting New Patients
Principal Investigator: Young Chae

Modular phase II study to link targeted therapy to patients with pathway activated tumors: Module 7 – Ceritinib (LDK378) for patients whose tumors have aberrations in ALK or ROS1

The purpose of this clinical trial is to study if ceritinib is safe and has beneficial effects in people who have different tumor types (cancer), and/or blood malignancies with an ALK or ROS1 activated pathway.

Status: Accepting New Patients
Principal Investigator: Young Chae

Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Cancer

The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is.

Status: Accepting New Patients
Principal Investigator: Jeffrey Raizer

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer

The purpose of this study is to compare the effects, good and/or bad, of radiation therapy alone versus radiation therapy and cetuximab on head and neck cancer after surgery.

Status: Accepting New Patients
Principal Investigator: Eric Donnelly

Extended Duration Varenicline for Smoking among Cancer Patients: A Clinical Trial

The main purpose of this research study is to compare 12 versus 24 weeks of varenicline treatment, also known as Chantix®, for smoking cessation.

Status: Accepting New Patients
Principal Investigator: Brian Hitsman

A Phase II Trial of Bevacizumab in Patients with Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy

The purpose of this study is to see what effect bevacizumab, the drug being tested, will have on brain disease from solid tumor cancers. This study will not evaluate the effect of bevacizumab on the systemic solid tumor cancer.

Status: Accepting New Patients
Principal Investigator: Priya Kumthekar

Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis

There are 2 parts to this study (phase II and phase III). The part of the study in which a participant is enrolled depends on the timing of starting in the study. The purpose of the phase II part of the study is to treat the cancer that has spread to a participant's spine, and is causing pain, with image-guided radiosurgery/SBRT. The purpose of phase III is to compare the effects, good and/or bad, of image-guided radiosurgery/SBRT to standard radiation therapy to find out which treatment provides the most rapid pain relief with the least side effects.

Status: Accepting New Patients
Principal Investigator: John Kalapurakal

last updated: Fri - May 06, 2016 - 02:30 PM

Fetching Clinical Trial!

 

Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.